



MySafePass™
Neurological Screening Technology

MySafePass™ Military & Government Solution

Trusted, Rapid Concussion & Neurological Symptom Screening

FDA Class II Medical Device

Enhancing Force Readiness Through Early Detection



60-Second Screening



Field Deployable



80% Cost Reduction



Executive Summary

The TBI Challenge

Traumatic Brain Injuries (TBIs) significantly impact military readiness and operational effectiveness:

-  383,000+ service members diagnosed with TBI since 2000
-  65-80% of mild TBI cases go undiagnosed or are detected late
-  \$13.5B+ annual cost to DoD for TBI treatment and lost duty time

Current Screening Limitations:

- Time-intensive diagnostic procedures (45-90 min)
- Requires specialized medical personnel
- Limited field deployment capability
- Subjective assessment prone to reporting bias

The MySafePass™ Solution

FDA Class II medical device providing rapid olfactory-based screening for early detection of TBI and neurological conditions.

Force Readiness Impact

Early detection of subtle TBIs preserves combat effectiveness and prevents long-term complications

Operational Efficiency

60-second screening deployable in field conditions with minimal training required

Fiscal Responsibility

70-80% cost reduction compared to traditional screening methods with improved detection rates



The Military TBI Crisis



MySafePass™

Neurological Screening Technology

383,000+

Service members diagnosed with TBI since 2000

82%


Of military TBIs classified as mild and often undetected

\$13.5B+

Annual cost to DoD for TBI treatment and lost duty time

TBI by Severity in Military


Distribution showing predominance of mild TBI cases



● Mild TBI (82%) ● Moderate (11%) ● Severe (7%)

Primary Causes of Military TBI

Training accidents and blast exposure are leading causes



Operational Impact



Combat Readiness

30% reduction in unit effectiveness due to undiagnosed TBI



Medical Resources

22% of military medical evacuations are TBI-related



Long-Term Health

Increased risk of PTSD, depression and cognitive decline

Current Screening Limitations

Comparing conventional TBI screening approaches with MySafePass™ solution



VS

Conventional TBI Screening



Time-Intensive

45-90 minutes required for complete neurological assessment



Specialized Personnel

Requires trained medical professionals with neurological expertise



Limited Field Capability

Most tests require clinical settings with specialized equipment



Subjective Assessment

Relies heavily on self-reporting and observer evaluation



High Cost

\$800-1,200 per comprehensive assessment

MySafePass™ Solution



60-Second Screening

Rapid olfactory assessment completed in under one minute



Minimal Training

Can be administered by any medical personnel with basic training



Field Deployable

Portable, rugged design suitable for any military environment



Objective Results

Standardized assessment with quantifiable measurements



Cost-Effective

\$95-150 per screening with higher detection sensitivity

Introducing MySafePass™



MySafePass™
Neurological Screening Technology

FDA Class II medical device for rapid screening of traumatic brain injury, neurological disorders, and infectious diseases through olfactory testing.

60-Second Rapid Screening

Fast, non-invasive assessment deployable in any environment

Clinically Validated

Based on proven correlation between olfactory dysfunction and neurological conditions

Digital Integration


Secure mobile app synchronizes with military health systems

Field-Ready

Ruggedized design for deployment in combat zones and austere environments



FDA Class II Medical Device (Exempt from 510k)



How MySafePass Works



MySafePass™

Neurological Screening Technology

MySafePass™ uses patented proprietary technology to test for olfactory scent disorders - a key indicator of TBI and neurological conditions. The simple 60-second process provides immediate results.




Step 1

Scan QR code on test card with mobile app



Step 2

Scratch 5 scent points on the olfactory test card



Step 3

Patient identifies scents and sensitivity levels



Step 4

App instantly processes data and analyzes results



Step 5

Results delivered to medical provider with clinical recommendations

Military-Grade Accuracy

Detects subtle olfactory dysfunction with 94% sensitivity to hyposmia indicating TBI

Field-Ready Deployment

Lightweight, portable kits requiring minimal training for field medics and combat support personnel

Secure Data Integration

Military-grade encryption with seamless integration into existing DoD healthcare systems

Scientific Foundation & Regulatory Status



MySafePass™

Neurological Screening Technology

The Science of Olfactory Screening

Olfactory dysfunction is a clinically proven early indicator of neurological disorders and TBI:



Mechanism: Olfactory bulbs connect directly to CNS, serving as sensitive indicators of neurological changes



Early Detection: Hyposmia precedes other symptoms in 90% of early-stage neurological cases



Diagnostic Accuracy: 85-92% sensitivity for mild TBI detection

Key Research Findings:

Science Direct (2023): A test of olfactory function and CTE would be a game-changer in understanding head injuries."

NIH (2024): "Olfactory dysfunction is among earliest features of TBI, present in ~90% of cases."

Full bibliography in technical documentation

Regulatory Validation & Approval

MySafePass™ has received FDA Class II medical device approval for field deployment:



FDA Class II Medical Device

Approved for clinical use in medical screening, exempt from 510(k) requirements



Military Standards Compliance

MIL-STD-810H: Environmental Engineering

MIL-STD-461G: Electromagnetic Compatibility

NATO STANAG 2548: Medical Evaluation Standards



Clinical Validation

12,000+ clinical cases validated across civilian healthcare

Successful pilot with Naval Special Warfare Medical Group

Validated by independent DoD neurological assessment teams



Military & Government Applications



MySafePass™

Neurological Screening Technology

MySafePass™ offers versatile deployment options across defense, homeland security, and government healthcare operations, enabling rapid screening for TBI, neurological disorders, and force health protection.

Combat Operations

- ✓ Field-ready concussion screening
- ✓ Rapid blast exposure assessment
- ✓ Combat readiness verification

Training & Readiness

- ✓ Pre/post training assessment
- ✓ Special operations baseline testing
- ✓ Repeated impact monitoring

Medical Operations

- ✓ Field hospital rapid triage
- ✓ MEDEVAC priority assessment
- ✓ MACE 2 protocol integration

Veterans Affairs

- ✓ VA facility neurological screening
- ✓ Service-connected disorder detection
- ✓ TBI/PCS patient monitoring

Defense Health Programs

- ✓ First responder screening
- ✓ Border personnel monitoring
- ✓ Mass public health screening

Enhancing Force Readiness



MySafePass™

Neurological Screening Technology

MySafePass™ directly impacts military effectiveness by providing immediate, field-ready detection of subtle neurological changes.

Mission Continuity

Rapidly identify affected personnel to maintain optimal team performance and operational readiness

Impact: 82% reduction in mission disruptions

Combat Effectiveness

Prevent compromised decision-making and reaction time by identifying concussed personnel

Impact: 65% increase in threat assessment accuracy

Personnel Protection

Prevent compounding injuries by identifying and treating initial TBIs before secondary impacts

Impact: 73% reduction in secondary impact syndrome

Force Readiness Scenario

During training at Fort Bragg, a Special Operations unit implemented MySafePass™ screening after explosive breaching drills:

- 12 operators screened in under 15 minutes
- 3 personnel identified with subtle changes
- 2 confirmed with mild TBI requiring intervention
- Zero mission-impacting delays

Readiness Workflow Integration



Pre-Operation
Baseline screening



Post-Exposure
Rapid assessment



Immediate Action
Clinical protocols

Field Deployment & Scalability

Rapid Field Deployment

MySafePass™ offers unmatched scalability for military operations with minimal logistical footprint:

Compact Deployment Kits

Individually packaged testing cards (100 tests/box) with sealed shelf-life of 24 months

Online/Offline Capability

App works with or without network connectivity - store & forward data when connection is available

Military-Grade Security

FIPS 140-2 compliant encryption, DoD-approved security protocols, secure data transmission

Minimal Training Required

Any medical technician or corpsman can be trained in under 30 minutes

⌚ 30-min training

👤 98% accuracy rate

📱 Standard device

Deployment Process

Streamlined integration into existing military medical protocols:



Distribution
Central to field



Integration
Unit protocols



Testing
60-sec screening



Reporting
Command data

Production Capacity

500,000+

Monthly test capacity

Distribution Reach

Global

All theaters of operation

Digital Integration

100%

MHS GENESIS compatible

Deployment Speed

72 hrs

From order to field delivery

Cost Analysis & ROI

Financial Impact

MySafePass™ delivers significant cost savings compared to traditional TBI screening:

Cost Per Screening

MySafePass™:	\$12.50
Traditional Methods:	\$85.00
Cost Reduction:	85%


Annual Cost at Brigade Level

MySafePass™ (5,000 tests):	\$62,500
Traditional Methods:	\$425,000
Annual Savings:	\$362,500


Additional ROI Factors:

- ✓ 70% reduction in personnel hours
- ✓ 92% less equipment needed
- ✓ \$1.2M saved in long-term care
- ✓ 14% increase in duty-ready status

Cost Comparison: MySafePass™ vs. Traditional



5-Year Cost Projection



Competitive Advantages



MySafePass™

Neurological Screening Technology

Key differentiators between MySafePass™ and industry alternatives

VS

Industry Competitors



Lengthy Assessment

20-60+ minutes for neurological screening protocols



Higher Cost

\$500-1,200 per assessment with additional specialist fees



Limited Sensitivity

Often misses subtle or early-stage neurological changes



Complex Implementation

Requires extensive training and specialized facilities



Limited Data Integration

Minimal integration with existing military medical systems

MySafePass™ Advantages



60-Second Screening

Rapid deployment with immediate results available



Cost-Effective

80% cost reduction with CPT-coded insurance billing



Enhanced Sensitivity

Detects subtle olfactory changes missed by standard protocols



Simple Implementation

Minimal training required with field-ready deployment



Full Data Integration


Seamless integration with military health information systems

Implementation Timeline



MySafePass™

Neurological Screening Technology



Pilot Program Proposal



Pilot Objectives

Validate MySafePass™ efficacy in military operational environments

- Deployment Testing:** Evaluate field performance in varied military environments
- User Experience:** Assess medical staff and end-user adoption rates
- Performance Metrics:** Gather comparative data vs. conventional screening
- Integration:** Validate compatibility with existing DoD medical systems

Recommended Pilot Structure

- ✓ 3 military bases
- ✓ 250 personnel/location
- ✓ 90-day evaluation
- ✓ Full technical support

Evaluation Metrics & Plan

Comprehensive assessment using established DoD performance criteria

Key Performance Indicators:

- TBI detection accuracy rate
- False positive/negative rates
- Average screening time
- User satisfaction scores
- Field deployment readiness
- Cost per detection comparison

Implementation Phases:



Success Criteria

- > 90% detection accuracy
- > 85% user satisfaction
- > 60% time reduction
- > 50% cost savings

Risk Mitigation & Change Management



MySafePass™

Neurological Screening Technology

Key Risk Areas

Proactively addressing implementation challenges across critical domains



User Adoption

Resistance to new protocols and technology integration within established military medical procedures



Information Security

Patient data protection, secure transmission protocols, and compliance with military cybersecurity standards



Regulatory Compliance

Ensuring alignment with DoD medical device policies, HIPAA requirements, and military health system protocols



Field Reliability

Performance verification in extreme environments and during high-tempo operations

Change Management Strategy

Comprehensive approach to ensure successful integration

1

Stakeholder Engagement

Early involvement of medical command, field medics, and unit commanders

2

Phased Implementation

Controlled rollout starting with pilot units and expanding based on feedback

3

Technical Integration

Secure API connections with existing military health records systems

4

Training & Certification

Comprehensive training program with certification and standard operating procedures









DISA/DoD Security Compliance Ready

Measuring Success: Key Metrics



Clearly defined metrics ensure program accountability and quantifiable ROI for military stakeholders



Citations & References



MySafePass™

Neurological Screening Technology

Sources used for statistical data and scientific claims presented in this briefing:

Military TBI Statistics

Defense and Veterans Brain Injury Center. (2024). DoD worldwide numbers for TBI. Military Health System.

Vanderploeg, R. D., et al. (2024). Mild traumatic brain injury in military service members and veterans. *Military Medicine*, 189(3), 326-338.

Congressional Budget Office. (2023). Veterans' disability compensation: Trends and policy options.

Olfactory Science & TBI Detection

Frank, M. E., Fletcher, D. B., & Hettinger, T. P. (2017). Recognition of the component odors in mixtures. *Chemical Senses*, 42(6), 537-546.

Reiter, E. R., & Costanzo, R. M. (2014). Chemosensory impairment after traumatic brain injury. *International Neurotrauma Letter*, 23, 3-5.

National Institute of Health. (2023). Olfactory dysfunction among the earliest nonmotor features of neurological disorders.

Regulatory & Clinical References

FDA. (2024). Medical devices; neurological devices; classification of the olfactory dysfunction screening device. *Federal Register*, 89(45).

Department of Defense. (2025). Military acute concussion evaluation 2 (MACE 2). Defense Health Agency Publication.

MySafePass. (2025). Clinical validation studies for olfactory dysfunction screening in TBI detection. FDA Class II Documentation.

Cost Analysis References

Government Accountability Office. (2024). Military health: Costs of traumatic brain injury and mental health care (GAO-24-589).

Military Health System Research Symposium. (2025). Cost-effectiveness analysis of early TBI detection methods in military settings.

Defense Health Agency. (2024). Annual report on medical readiness and field screening technology cost analysis.

Images: Department of Defense Visual Information Library, FDA Medical Device Gallery, and MySafePass™ corporate materials.